Evaluating new antimalarial drugs against trophozoite induced Plasmodium cynomolgi malaria in rhesus monkeys.
An antimalarial drug testing system is described which utilizes trophozoite induced Plasmodium cynomolgi malaria in rhesus monkeys. The schizonticidal activity of standard antimalarial drugs in this system is reported. The system accurately predicted antimalarial activity in man of 8 of 9 compounds selected for clinical trials.
D000655:Amodiaquine / Q000627:therapeutic use; D000818:Animals; D000962:Antimalarials / Q000627:therapeutic use*; D003622:Dapsone / Q000627:therapeutic use; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004353:Drug Evaluation, Preclinical; D004361:Drug Tolerance; D000882:Haplorhini; D008253:Macaca mulatta; D008288:Malaria / Q000188:drug therapy*; D010616:Phenanthrenes / Q000627:therapeutic use; D011319:Primaquine / Q000627:therapeutic use; D011353:Prodigiosin / Q000627:therapeutic use; D011739:Pyrimethamine / Q000627:therapeutic use; D011803:Quinine / Q000627:therapeutic use; D013411:Sulfadiazine / Q000627:therapeutic use; D013412:Sulfadimethoxine / Q000627:therapeutic use; D013415:Sulfalene / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use
D000962:Antimalarials; D010616:Phenanthrenes; D013411:Sulfadiazine; D000655:Amodiaquine; D013412:Sulfadimethoxine; D003622:Dapsone; D011803:Quinine; D014295:Trimethoprim; D011319:Primaquine; D011353:Prodigiosin; D013415:Sulfalene; D011739:Pyrimethamine